Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0000950170-24-026760 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-05 | 2024-03-01 | CORT | Mokari Atabak | CFO | F - Tax | $24.06 | -517 | 8,428 | -6% | -$12.4K | |
| M | 2024-03-05 | 2024-03-01 | CORT | Mokari Atabak | CFO | A - Grant | $12.03 | +1,108 | 8,982 | +14% | +$13.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | F | D | 517 | $24.06 | 8,428 | D | — | — | (F2) Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2024-03-01 | A | A | 554 | $0.00 | 9,536 | D | — | — | (F5) Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. (F2) Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 3 | Common | Common Stock | 2024-03-01 | A | A | 554 | $24.06 | 8,982 | D | — | — | (F3) The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. (F4) In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. (F2) Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |